更新于：2024-11-05
Bisoprolol
比索洛尔
更新于：2024-11-05
概要
基本信息
药物类型 小分子化药 |
别名 Concor、Nerkardou、EMD 33 512 + [3] |
作用机制 β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂)、β2-adrenergic receptor拮抗剂(β2-肾上腺素能受体拮抗剂) |
治疗领域 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H31NO4 |
InChIKeyVHYCDWMUTMEGQY-UHFFFAOYSA-N |
CAS号66722-44-9 |
关联
107
项与 比索洛尔 相关的临床试验Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects: a Randomized, Double-blind, Cross-over Study
Effect of Bisoprolol and Metoprolol in reducing heart rate in coronary CT-angiography candidates: a double-blind randomized clinical trial
STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
100 项与 比索洛尔 相关的临床结果
登录后查看更多信息
100 项与 比索洛尔 相关的转化医学
登录后查看更多信息
100 项与 比索洛尔 相关的专利（医药）
登录后查看更多信息
1,864
项与 比索洛尔 相关的文献（医药）2024-12-01Annales de cardiologie et d'angeiologie
La fibrillation atriale à l'Hôpital Principal de Dakar au Sénégal : résultats et limites de la prise en charge
Article
作者: Tidiane, Ndao Serigne Cheikh ; Cherif, Mboup Mouhamed ; Niang, Mboup Waly ; Khadidiatou, Dia ; Marième, Diop ; Rabab, Yassine ; Madjiguène, Ka Mame
OBJECTIVES:
The aim of the study was to determine the prevalence of AF in the cardiology department of the Hospital Principal of Dakar, then to evaluate the clinical, paraclinical, etiological and evolutionary profiles of AF and finally to identify the limits of its management in our context.
PATIENTS AND METHODS:
This was a retrospective, descriptive, analytical, mono-centric study carried out at Hospital Principal of Dakar from January 2019 to August 2021. Were included, all patients admitted for atrial fibrillation, or patients who presented an atrial fibrillation during hospitalization, confirmed by electrocardiogram or long-term electrocardiographic recording during the study period.
RESULTS:
The prevalence of atrial fibrillation during the period of our study compared to the hospital population was 7.71%, with a sex ratio of 1.03. The mean age was 67.88 ± 14.09 years. We noted that 83.64% of patients had at least one cardiovascular risk factor, with 56.36% suffering from hypertension, 50.91% of sedentary person and 23.64% of diabetics. Clinically, 92.72% of the patients were symptomatic, with dyspnea predominating (70.91%). Cardiac arrhythmia was present in 85.45% of patients, and congestive heart failure in 47.27%. Long-term electrocardiographic recording was performed in 10 patients, showing 50% of paroxysmal atrial fibrillation. Sixty-three patients (57.27%) had permanent AF, twenty-three patients (20.91%) had persistent AF, fourteen patients (12.73%) had long-term persistent AF and ten patients (9.09%) had paroxysmal AF. Transthoracic echocardiography showed 57.27% of left atrial dilatation and 72.3% of reduced left ventricular ejection fraction. Etiologies for cardiac causes were dominated by dilated cardiomyopathy (21.82%), followed by ischemic heart disease (17.27%). In terms of treatment, the most commonly used molecule was bisoprolol (38.18%), followed by digoxin (21.81%). Anticoagulants were used in 85.46% of cases. Acenocoumarol alone was used in 69.09% of patients. Drug-induced cardioversion was attempted in 2 patients without success, and 4 patients benefited from external electric shock with 3 successes. Most patients had a favorable outcome, but 34.54% suffered hemodynamic complications (18.18%) and thromboembolic ones as well (16.36%). In-hospital mortality in our series was 20%. It was significantly related to heart failure, with a left ventricular ejection fraction < 35% (p < 0.001).
CONCLUSION:
Atrial fibrillation is serious because of its hemodynamic, thromboembolic and rhythmic complications. The high mortality is explained by the underlying condition, but also by the delay in management with late diagnosis and, above all, the unavailability of ablation procedures in our context.
2024-12-01Cardiovascular & hematological agents in medicinal chemistry
Article
作者: Almeman, Ahmad Abdulrahman ; Alwahhabi, Abdulaziz Sulaiman ; Alnasr, Moayad Yousef ; Almutairi, Abdulaziz Abdullah ; Alharbi, Yousef Obaid ; Almesnid, Abdulrahaman
Background::
Beta-blockers are essential agents in the management of cardiovascular
diseases, such as heart failure, acute myocardial infarction (MI), and cardiac arrhythmias. However,
there are diurnal variations in the cardioprotective effects of the subgroups as a result of
their different pharmacokinetic, pharmacodynamic, and pharmacogenetic profiles
Objectives::
We aimed to compare metoprolol and bisoprolol in terms of electrocardiogram
(ECG) outcomes.
Methods::
A retrospective cross-sectional study was conducted at Prince Sultan Cardiac Center.
The trial included 404 patients who met the inclusion criteria (204 in the metoprolol arm and 200
in the bisoprolol arm). Using case record forms that had already been created, information, such
as patient demographics, medical histories, and treatment histories, was taken from their medical
files. The most recent ECG records were also gathered. The ethical approval for this study was
obtained from Qassim ethical committee (approval number: 45-44-902).
Results::
There was no significant difference found between the patients in both arms in terms of
baseline characteristics, age, or sex.
Conclusion::
In this retrospective cross-sectional study, we have compared the effects of
metoprolol and bisoprolol beta blockers on ECG changes. The findings have indicated no difference
between metoprolol and bisoprolol groups in terms of all ECG readings, particularly
PR/ms, QTC-ms, and ventricular rate. Further studies are required to confirm these findings.
2024-12-01Toxicology reports
Article
作者: Goffredo, B M ; Marano, M ; Perdichizzi, S ; Faraci, S ; Torroni, F ; Di Nardo, M ; Gowda, Sharada H
Introduction:
Intentional multiple drugs overdose is an often-encountered method of self-harm in adolescence. Treatments include supportive therapy, antidotes (when available) and decontamination techniques with the aim of reducing drugs absorption by the gastrointestinal system to minimize toxicity. Nevertheless, the decontamination techniques currently used, such as gastric lavage (GL), activated charcoal or whole-bowel irrigation, have a questionable effectiveness. Endoscopic gastric decontamination (EGD) treatment for massive ingestion of drugs or formation of pharmacobezoars is currently described only in anecdotal cases. Here we describe the management of an intentional drug overdose in an adolescent patient treated with EGD and the effects of this therapy on drugs pharmacokinetics.
Case report:
A 15-year-old boy was admitted in an unconscious state (Glasgow Coma Scale: 7-8) to the pediatric intensive care unit after assuming an unspecified amount of quetiapine, aspirin, bisoprolol, fluoxetine, furosemide, alprazolam, and pregabalin pills. Rapid sequence intubation was immediately performed and then the patient was treated with symptomatic therapy and GL with minimal removal of gastric material. Accounting for the type of drugs, the time elapsed from oral assumption and the unknown quantity assumed, EGD was attempted with aim of removing potential aggregate of the drugs. Serial blood samples were taken before and after EGD to measure the plasma level of the drugs. A pharmacobezoar was found and was immediately removed with EGD. The results of the drug monitoring showed that quetiapine exceeded the toxic level reported in literature indicating that it may have been the drug assumed in higher quantity by our patient. PICU stay was uneventful, and the patient was transferred to the psychiatric ward after extubation.
Discussion:
Our case shows how GL is not effective in mitigating multidrug absorption especially drugs potentially inducing pharmacobezoars. Furthermore, based on our plasma drug monitoring, we believe that early EGD should be considered in all cases of massive pill intake, prolonged release drugs that can form pharmacobezoars or in cases where a life-threatening dose cannot be excluded.
100 项与 比索洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心房颤动 | 日本 | 2013-06-28 | |
| 原发性高血压 | 日本 | 2013-06-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 515 | 醖醖積廠餘築築簾製顧(築構構窪網壓憲齋鬱齋) = 顧願鏇簾衊獵憲齋構憲 遞獵獵積築窪壓襯糧窪 (襯構淵鏇鹹襯膚鏇繭餘 ) 更多 | 不佳 | 2024-08-13 | |||
Placebo | 醖醖積廠餘築築簾製顧(築構構窪網壓憲齋鬱齋) = 膚膚齋夢憲壓窪襯觸憲 遞獵獵積築窪壓襯糧窪 (襯構淵鏇鹹襯膚鏇繭餘 ) 更多 | ||||||
临床4期 | 5,020 | metoprolol or bisoprolol | 構餘窪憲壓觸廠鑰糧廠(築顧願襯選願膚構繭獵) = 襯築淵願顧襯餘製艱壓 遞窪夢鹽憲蓋鏇願齋製 (艱簾衊蓋鹹積網獵醖壓 ) 更多 | 不佳 | 2024-04-07 | ||
no-Beta-Blockers | 構餘窪憲壓觸廠鑰糧廠(築顧願襯選願膚構繭獵) = 廠淵膚壓夢餘醖鏇憲廠 遞窪夢鹽憲蓋鏇願齋製 (艱簾衊蓋鹹積網獵醖壓 ) 更多 | ||||||
N/A | 200 | Bisoprolol 5 mg | 繭衊淵糧醖選襯鹽鹽憲(鬱鏇壓繭糧齋鏇積積壓) = 構憲廠觸衊淵壓壓膚鑰 鏇構蓋夢襯願醖憲鏇艱 (鏇構鹽選窪醖製鹽襯獵 ) 更多 | - | 2021-08-27 | ||
Metoprolol-SR 50 mg | 繭衊淵糧醖選襯鹽鹽憲(鬱鏇壓繭糧齋鏇積積壓) = 憲廠壓壓衊觸淵憲積襯 鏇構蓋夢襯願醖憲鏇艱 (鏇構鹽選窪醖製鹽襯獵 ) 更多 | ||||||
临床4期 | 161 | (Beta-blocker) | 鬱夢繭顧衊鏇齋網獵齋(憲艱鏇夢願構襯艱築廠) = 製構簾鏇範鏇製廠簾構 獵築鬱願獵淵鑰觸糧觸 (觸鏇觸觸遞夢壓蓋遞醖, 鑰衊鹽鹹選醖淵簾網淵 ~ 網觸積願艱醖淵壓選繭) 更多 | - | 2021-06-16 | ||
(Digoxin) | 鬱夢繭顧衊鏇齋網獵齋(憲艱鏇夢願構襯艱築廠) = 製築積觸範選廠憲網廠 獵築鬱願獵淵鑰觸糧觸 (觸鏇觸觸遞夢壓蓋遞醖, 鑰製夢簾範鏇願願網膚 ~ 鬱顧築壓鹽積觸獵鑰鏇) 更多 | ||||||
N/A | - | - | Highly dialyzable BB (HDBB) | 製夢遞鹽鏇齋艱積衊廠(鏇願鹽夢膚簾構願獵顧): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多 | 不佳 | 2020-10-19 | |
Poorly dialyzable BB (PDBB) | |||||||
临床4期 | 20 | 鑰蓋憲製鏇構獵鹹積淵(醖製襯鏇廠醖憲齋鬱鏇) = 艱襯範淵廠選構淵願簾 淵積夢蓋鬱餘夢築醖顧 (衊選鏇製襯襯網齋窪鹽, 餘窪構蓋淵遞構壓糧襯 ~ 鹽積憲艱繭鹽餘淵衊構) 更多 | - | 2020-01-29 | |||
N/A | 282 | 築網壓積製壓衊築鏇構(鹹夢構鑰遞餘積鏇觸製) = 顧艱廠構艱窪衊構製窪 鑰窪繭鏇憲廠餘鑰鹽餘 (鹽糧選範膚鬱壓廠積遞 ) | - | 2019-09-03 | |||
築網壓積製壓衊築鏇構(鹹夢構鑰遞餘積鏇觸製) = 願鏇壓餘積壓遞廠鏇選 鑰窪繭鏇憲廠餘鑰鹽餘 (鹽糧選範膚鬱壓廠積遞 ) | |||||||
N/A | 尿毒症 维持 | - | 憲遞簾夢繭憲築製廠蓋(淵膚夢繭襯窪製齋積選): P-Value = 0.96 更多 | 积极 | 2019-06-13 | ||
N/A | 急性冠状动脉综合征 CYP3A5 * 1 | CYP3A5 * 3 | 102 | 積艱鹽廠鹹積壓淵壓鑰(廠醖廠願糧夢廠鹹壓鹹) = 襯鹽願餘鑰膚鏇鏇鬱醖 蓋網齋鹹壓簾顧衊鹹願 (製夢淵網夢淵餘艱壓鹽 ) 更多 | - | 2018-08-28 | ||
積艱鹽廠鹹積壓淵壓鑰(廠醖廠願糧夢廠鹹壓鹹) = 範壓夢積網鑰憲鏇觸壓 蓋網齋鹹壓簾顧衊鹹願 (製夢淵網夢淵餘艱壓鹽 ) 更多 | |||||||
N/A | 59 | 廠鏇鏇鹽壓遞襯範鹽鏇(構壓蓋鏇衊鑰遞獵淵獵) = bradycardia occurred in three patients of combination treatment group 糧積鹹築膚繭願襯範膚 (廠蓋鏇餘醖壓鏇觸積齋 ) | - | 2018-01-22 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用